COMPANY RESEARCH
CTT PHARMACEUTICAL HOLDINGS, INC.
CTTH · United States · Healthcare
INSIDER SIGNAL
Insider activity score：39.1 / 100
1 insiders · 13 purchase events · $5k net purchases
US #854 · United States #854
WHY THIS SIGNAL?
Score anatomy
Each bar shows the contribution to the current score; the weights and formula stay unchanged.
Cluster+7.0 / 35
How many distinct insiders bought in the cluster
Purchase size+0.9 / 25
Purchase value relative to company size and liquidity
Role+7.0 / 20
The seniority and relevance of participating insiders
Recency+8.2 / 10
How recently the purchases occurred
Conviction+10.0 / 10
How clearly buying stands out from other activity
What is holding the score back?
- ⚠ Buyer breadth is moderate · fewer than 4 distinct filers
- ⚠ Purchase size is modest relative to the model scale
- ⚠ Insider role contributes less on the current role scale
- ✓ Recent activity · latest purchase 2026-10-06
The role contribution follows the US model's seniority ladder.
Buying concentration
100%
Largest buyer：CTT PHARMACEUTICAL HOLDINGS, INC. · 5k USD
Gross qualified purchase transaction-line value：5k USD
The headline $ total is net buying for the screen; this module uses gross qualified purchase transaction-line values in the filing currency, so the amounts can differ. The current 15-day buyer-breadth input counts distinct buyers; value concentration is disclosed separately here.
This is a ranking under the current US screening rules—not a probability of gain, return forecast, or buy recommendation.
Key purchase quotes (filing currency)
| Filer | Price per unit | Trade date |
|---|---|---|
| CTT PHARMACEUTICAL HOLDINGS, INC. | 0.055 USD | Oct 6, 2026 |
| CTT PHARMACEUTICAL HOLDINGS, INC. | 0.06 USD | Sep 28, 2026 |
| CTT PHARMACEUTICAL HOLDINGS, INC. | 0.05 USD | Sep 22, 2026 |
Model details
Cluster breakdown (does not change the score)
- 15-day buyer breadth (count)
- 1 distinct reported filers
- Peak time window
- 2026-08-07 to 2026-08-20
- Current breadth input
- 0.200 (capped at 4+ buyers)
- Buyer independence
- Not yet measured; related-party fields are not cross-market comparable
What the filings show
- 🟢 Recent eligible purchase
CTT PHARMACEUTICAL HOLDINGS, INC. · 204 USD · Price 0.055 USD · Oct 6, 2026 - 🟢 Eligible purchase
CTT PHARMACEUTICAL HOLDINGS, INC. · 204 USD · Price 0.06 USD · Sep 28, 2026 - 🟢 Large eligible purchase
CTT PHARMACEUTICAL HOLDINGS, INC. · 1k USD · Price 0.05 USD · Sep 22, 2026 - 🟡 10 remaining qualified transaction line(s) across 10 disclosure(s)
Insider vs stock price
13 purchase day(s), 14 purchase line(s) in the 180-day window.
Daily close (USD)Day with an insider purchase
Markers sit on the closing price of the transaction day. They show when insiders traded, not the price they paid or received. "Since" compares that day's close with the last close shown; it is what happened at this company, not a forecast.
If you had followed the purchase
Each row starts on the first close on or after the day a purchase was made public, the earliest a reader could have acted, and ends on the last close shown above.
| Made public | Insiders | In this stock, now | In the median peer stock, now | Difference |
|---|---|---|---|---|
| 2026-08-10 | 1 | 877 −12.3% | 919 −8.1% | −42 −4.2 pts |
| 2026-08-14 | 1 | 933 −6.7% | 910 −9.0% | +22 +2.2 pts |
| 2026-08-19 | 1 | 1,029 +2.9% | 916 −8.4% | +113 +11.3 pts |
| 2026-08-20 | 1 | 976 −2.4% | 918 −8.2% | +58 +5.8 pts |
| 2026-08-24 | 1 | 993 −0.7% | 916 −8.4% | +77 +7.7 pts |
| 2026-08-31 | 1 | 1,161 +16.1% | 925 −7.5% | +235 +23.5 pts |
| 2026-09-02 | 1 | 1,158 +15.8% | 924 −7.6% | +233 +23.3 pts |
| 2026-09-04 | 1 | 1,168 +16.8% | 920 −8.0% | +248 +24.8 pts |
| 2026-09-10 | 1 | 1,093 +9.3% | 944 −5.6% | +148 +14.8 pts |
| 2026-09-16 | 1 | 1,182 +18.2% | 964 −3.6% | +218 +21.8 pts |
| 2026-09-22 | 1 | 993 −0.7% | 960 −4.0% | +33 +3.3 pts |
| 2026-09-28 | 1 | 995 −0.5% | 983 −1.7% | +12 +1.2 pts |
| 2026-09-29 | 1 | 995 −0.5% | 987 −1.3% | +7 +0.7 pts |
| 2026-10-06 | 1 | 1,000 +0.0% | 991 −0.9% | +9 +0.9 pts |
13 of 14 disclosure day(s) ended ahead of the median peer stock.
Close to close, before costs, taxes, dividends and currency moves. The peer is the median of the other stocks on the same exchange for which this site holds prices (1092 here), not an index. This is what happened, not a forecast: across all purchases on this site the typical gap is close to zero.
Insider timeline
One insider bought, 13 times, the latest (6 Oct). The share closed at 0.06 that day and at 0.06 most recently (+0.0%).
Tap an item for what it means.
●A purchase: the bigger the dot, the more was bought
Each dot is one insider's purchases on one day. The dot's area follows the amount: the largest purchase here gets the largest dot. Hold the pointer over a dot to see the date and the amount.
Blue line: this share's price, −18.3% over these six months
The closing price of each day, from 0.07 on 2026-04-21 to 0.06 on 2026-10-09. The line has no scale; read it for high and low: a dot on a low stretch was bought cheaply, a dot on a high stretch was not.
Dashed line: the typical stock on the same exchange, −11.0%
Taken from the 1230 other stocks on the same exchange that this site holds prices for. Each is measured from the first day of the window, and every day the middle one is drawn. It starts where the blue line starts, so the gap between the two is the difference: this share −18.3%, the typical one −11.0%, 7.2 points behind. It is not an index and not a comparison within one industry.
▂Grey bars: companies across United States disclosing purchases each week
A taller bar is a week in which more companies disclosed insider purchases.
This company: insiders buying per month, last 12 months
1Nov
1Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
1Aug
1Sep
1Oct
Darker bars are inside the 180-day window above.
Who traded
| Insider | Role | Purchases | Sales | Bought | First purchase | Share price since |
|---|---|---|---|---|---|---|
| CTT PHARMACEUTICAL HOLDINGS, INC. | CEO / chair | 13 | — | 4.9k USD | 2026-08-07 | −14.2% |
Why this score? · Model details
Priority = 100 × Σ(fixed weight × 0–1 rule-based input)
| Factor | Weight | This company input | Point contribution |
|---|---|---|---|
| 15-day buyer breadth (count) | 35% | 0.200 | 7.0 |
| Qualified-buy size | 25% | 0.036 | 0.9 |
| Role informativeness (inverted) | 20% | 0.650 | 13.0 |
| Recency | 10% | 0.819 | 8.2 |
| Buy/sell conviction | 10% | 1.000 | 10.0 |
This is a heuristic ordering under the current rules, not a calibrated return forecast. It explains why candidates rank differently; the public-filing evidence and data limits are shown below.
BULL VS BEAR
Two readings of this buying
The same filings, read two ways. Each line is a fact stored for this company with the number behind it, and appears only when that number crosses a fixed threshold. Neither side is a forecast and no winner is declared.
Where the evidence comes from
Independent evidence does not object: the purchases themselves carry bull lines (large purchases, bought in the last two weeks); share price and trading, short sellers, company results were checked and none crosses a bear threshold. No data is held for: company actions.
- The insider purchases themselvesBulllarge purchases, bought in the last two weeks Bearone buyer only, purchase added little to the holding4 checked, under the threshold · 1 missing
- Share price and trading2 checked, under the threshold
- Short sellers1 checked, under the threshold
- Company results1 checked, under the threshold · 1 missing
- Company actionsno data held
Bull case · the buying is informative
- Net purchases of $4,900 equal 0.16% of the company's market value ($3.0M): large for the size of the business.
- The latest purchase is 12 days old (2026-10-06). The buying is current, not left over from an earlier quarter.
Bear case · discount it
- Only one insider bought. A single purchase can reflect that person's own finances rather than a view on the company.
- 12 of 14 purchase filings state the shares held before and after. Each purchase added less than 1% to what the filer already held; the largest took a holding from 1,046,700 to 1,056,800 shares (+0.96%). A holding here is one way of owning the shares: directly, or through one named trust or entity.
Evidence still missing
- No buyer here has 5 or more completed earlier purchases on record, so there is no track record to weigh.
- Only one reading of profitability is held (profit margin <0.01%). Whether earnings and cash flow are rising or falling needs the last two reports side by side.
Checked and under the threshold: 8, 1 close to it
- BearOver three months the share price changed −29% and the median of 219 Healthcare companies changed −12%: behind by 17 points. Counted for the bear side from 20 points behind. close to the threshold
- Either1 insider bought in the last 180 days and 1 in the 180 days before. Bull when the number at least doubles and rises by two; bear when at least two bought before and no more buy now.
- BearNo insider sale is recorded in the same 180 days.
- BearThe share price changed −14% over six months (three months −29%, one month +9.3%) and stands 63% below its 52-week high. Counted for the bear side from a fall of 20%.
- BearNone of the 12 purchase filings ticks Form 4's 10b5-1 box.
- BearNo insider filing in the last 180 days opened a hedge on this stock.
- BearFINRA short interest on 2026-09-30 equals 1.0 days of average trading volume and 0.03% of the 59,722,232 shares outstanding, up 76% from the previous report. Counted for the bear side from 10 days, or from 10% of the shares outstanding.
- BearProfit margin on the latest captured figures is <0.01%. Counted for the bear side when negative.
Both columns arrange stored facts only. They do not change the insider score or the ranking and are not investment advice.
Signal history
39.1 / 100
Latest recorded score
↓ -8.4 ptssince the first recorded snapshot on 2026-10-09; 9 calendar days observed
- Recorded snapshots
- 7
- First snapshot
- 2026-10-09
There is not yet a 30-calendar-day comparison; earlier scores are not reconstructed. These are raw signal scores saved when each full scoring run completed. They describe changes in research ranking, not price performance or returns.
Why did it change?
Less than 30 days of comparable history is available, so factor movement is not yet decomposed.
Signal score history
Fixed 0–100 scale; dates are spaced by calendar time.
Recent recorded points
- 47.5
- 39.8
- 39.6
- 39.5
- 39.1
View all recorded scores
| Snapshot date | Signal score |
|---|---|
| 2026-10-09 | 47.5 |
| 2026-10-12 | 40.0 |
| 2026-10-13 | 39.8 |
| 2026-10-14 | 39.6 |
| 2026-10-15 | 39.5 |
| 2026-10-16 | 39.3 |
| 2026-10-18 | 39.1 |
Sector context
- Buying breadth
- 4.1% (42 / 1,029 issuers)
- Sector rank
- #8 / 13
This is sector-level research context. It does not affect the Insider Signal or ranking.
Insider profile outcomes
Historical performance following insider filings. The company role is translated below each name while preserving the original title.
- Excess return = stock return − S&P 500 ETF (SPY adjusted close) return over the same period.
- Hit rate = completed events with positive excess return ÷ total completed events.
- Price coverage = valid point-in-time prices ÷ events mature enough for that period.
- Returns start on the first shared trading session on or after publication.
- Small-sample rule: n<5 is shown for transparency and is not scored.
Events are disclosure-level observations; related disclosures published on the same date may share a return path and may not be statistically independent. This research enrichment does not affect the insider score or ranking.
Signal outcomes
Calculated from immutable US ranking snapshots; excess return is stock return minus SPY return. Newly saved snapshots remain pending until each forward horizon matures. This never affects the US score.
| Horizon | Status | Result |
|---|---|---|
| 5D | Awaiting maturity | — |
| 20D | Awaiting maturity | — |
| 60D | Awaiting maturity | — |
| 120D | Awaiting maturity | — |
Market context
PRICE PERFORMANCE
VOLATILITY & LIQUIDITY
- Volatility
- 193.6%
- Beta
- 0.72
- Avg daily volume
- $2,066.7
VALUATION
- Market cap
- $3.0M
- P/E
- —
FUNDAMENTALS
- Profit margin
- 0.0%
- ROE
- —
- Industry
- Drug Manufacturers - Specialty & Generic
Prices to 12 Oct 2026: OpenBB/yfinance. From OpenBB/yfinance, captured 02 Oct 2026: Market cap, P/E, Profit margin, Beta, Industry. It does not affect the insider score or rank.
Insiders' buying price vs the latest close
The latest close in the price history is more than a week old.
Buying size vs market trading
Complete price and volume history is not yet available.
Market-data coverage: 0 verified sessions · Latest session: — · Ratio status: Unavailable
Traded value is estimated as close × shares traded, in major currency units. Includes disclosed qualifying purchases; disclosures may lag. Contractual or planned acquisitions are not necessarily discretionary. Ratios describe relative trading size, not market participation or score contributions.
Regulatory filings
- Insider filing announcement · published 2026-10-06 · trade date 2026-10-06
- Insider filing announcement · published 2026-09-29 · trade date 2026-09-22
- Insider filing announcement · published 2026-09-28 · trade date 2026-09-28
Unfold all 18 filings
- Insider filing announcement · published 2026-10-06 · trade date 2026-10-06
- Insider filing announcement · published 2026-09-29 · trade date 2026-09-22
- Insider filing announcement · published 2026-09-28 · trade date 2026-09-28
- Insider filing announcement · published 2026-09-22 · trade date 2026-09-22
- Insider filing announcement · published 2026-09-16 · trade date 2026-09-16
- Insider filing announcement · published 2026-09-10 · trade date 2026-09-10
- Insider filing announcement · published 2026-09-04 · trade date 2026-09-04
- Insider filing announcement · published 2026-09-02 · trade date 2026-09-02
- Insider filing announcement · published 2026-08-31 · trade date 2026-08-31
- Insider filing announcement · published 2026-08-24 · trade date 2026-08-24
- Insider filing announcement · published 2026-08-20 · trade date 2026-08-20
- Insider filing announcement · published 2026-08-19 · trade date 2026-08-19
- Insider filing announcement · published 2026-08-14 · trade date 2026-08-14
- Insider filing announcement · published 2026-08-10 · trade date 2026-08-07
- Insider filing announcement · published 2025-12-17 · trade date 2025-12-17
- Insider filing announcement · published 2025-11-24 · trade date 2025-11-20
- Insider filing announcement · published 2025-11-21 · trade date 2025-11-20
- Insider filing announcement · published 2025-10-31 · trade date 2025-10-31
Results and insider purchases
No results announcement (8-K Item 2.02) from this company was found in its SEC filings.
Ownership and trading-plan context
| Direct / indirect ownership | Direct |
|---|---|
| 10b5-1 filing evidence | Not declared in filing field |
| Evidence retrieved | 2026-10-09T22:13:41+00:00 |
These are accession-level filing fields. Unavailable means the evidence was not fetched or parsed; it is never inferred as “No” and does not adjust the US score.
Filing evidence
These are underlying national-feed records from the 365-day window ending on the saved ranking snapshot. The score uses only the latest 180 days; older qualifying equity purchases remain visible for audit but do not enter the current score. The original filer, role, transaction classification, instrument, price, volume, value and source fields are retained. The first three rows are shown; remaining records can be unfolded for audit. Other transaction types are retained but excluded from the score.
Excluded transactions & classification
18 qualifying purchase disclosure(s) · 18 transaction line(s)
Dec 17, 2025Open market purchase
CTT PHARMACEUTICAL HOLDINGS, INC. · CEO
CTTH · 8300.0 shares × 0.06 USD · 498.0 USD
Open filingNov 20, 2025Open market purchase
CTT PHARMACEUTICAL HOLDINGS, INC. · Director
CTTH · 200000.0 shares × 0.04 USD · 8000.0 USD
Open filingNov 20, 2025Open market purchase
CTT PHARMACEUTICAL HOLDINGS, INC. · CEO
CTTH · 62900.0 shares × 0.04 USD · 2516.0 USD
Open filingUnfold all 15 remaining filing row(s)
| Transaction date | Published | Filer | Role | Transaction | Instrument | Price (local currency) | Quote currency | Volume | Reported value (local currency) | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-10-31 | 2025-10-31 | CTT PHARMACEUTICAL HOLDINGS, INC. | CEO | Open market purchase | CTTH | 0.06 USD | USD | 7000.0 | 420.0 USD | Open filing |
| 2026-09-28 | 2026-09-28 | CTT PHARMACEUTICAL HOLDINGS, INC. | CEO | Open market purchase | CTTH | 0.06 USD | USD | 3400.0 | 204.0 USD | Open filing |
| 2026-09-22 | 2026-09-29 | CTT PHARMACEUTICAL HOLDINGS, INC. | CEO | Open market purchase | CTTH | 0.05 USD | USD | 10100.0 | 505.0 USD | Open filing |
| 2026-09-22 | 2026-09-22 | CTT PHARMACEUTICAL HOLDINGS, INC. | CEO | Open market purchase | CTTH | 0.05 USD | USD | 10100.0 | 505.0 USD | Open filing |
| 2026-09-16 | 2026-09-16 | CTT PHARMACEUTICAL HOLDINGS, INC. | CEO | Open market purchase | CTTH | 0.05 USD | USD | 10900.0 | 545.0 USD | Open filing |
| 2026-09-10 | 2026-09-10 | CTT PHARMACEUTICAL HOLDINGS, INC. | CEO | Open market purchase | CTTH | 0.05 USD | USD | 3500.0 | 175.0 USD | Open filing |
| 2026-09-04 | 2026-09-04 | CTT PHARMACEUTICAL HOLDINGS, INC. | CEO | Open market purchase | CTTH | 0.05 USD | USD | 9800.0 | 490.0 USD | Open filing |
| 2026-09-02 | 2026-09-02 | CTT PHARMACEUTICAL HOLDINGS, INC. | CEO | Open market purchase | CTTH | 0.05 USD | USD | 3000.0 | 150.0 USD | Open filing |
| 2026-08-31 | 2026-08-31 | CTT PHARMACEUTICAL HOLDINGS, INC. | CEO | Open market purchase | CTTH | 0.05 USD | USD | 3500.0 | 175.0 USD | Open filing |
| 2026-08-24 | 2026-08-24 | CTT PHARMACEUTICAL HOLDINGS, INC. | CEO | Open market purchase | CTTH | 0.06 USD | USD | 2100.0 | 126.0 USD | Open filing |
| 2026-08-20 | 2026-08-20 | CTT PHARMACEUTICAL HOLDINGS, INC. | CEO | Open market purchase | CTTH | 0.05 USD | USD | 11500.0 | 575.0 USD | Open filing |
| 2026-08-19 | 2026-08-19 | CTT PHARMACEUTICAL HOLDINGS, INC. | CEO | Open market purchase | CTTH | 0.06 USD | USD | 10000.0 | 600.0 USD | Open filing |
| 2026-08-14 | 2026-08-14 | CTT PHARMACEUTICAL HOLDINGS, INC. | CEO | Open market purchase | CTTH | 0.06 USD | USD | 1800.0 | 108.0 USD | Open filing |
| 2026-08-07 | 2026-08-10 | CTT PHARMACEUTICAL HOLDINGS, INC. | CEO | Open market purchase | CTTH | 0.07 USD | USD | 7700.0 | 539.0 USD | Open filing |
| 2026-10-06 | 2026-10-06 | CTT PHARMACEUTICAL HOLDINGS, INC. | CEO | Open market purchase | CTTH | 0.055 USD | USD | 3700 | 203.5 USD | Open filing |
Showing 18 of 18 matching raw-feed row(s) from the current 365-day research window. Prices and reported values remain in the filing currency and its major unit (for example, UK pence are parsed as GBP). The screen-level $ aggregate is separately FX-normalised for research ranking, not a trade-date conversion.
Other disclosed transactions · excluded from score
The underlying filing feed is unavailable in this snapshot; this is not a claim that no filings exist.
Snapshot & identity
- Snapshot date
- 2026-10-18
- Ticker
- CTTH
- ISIN
- —
- Sector
- Healthcare
- Industry
- —
Company logos by Parqet
How to read Form 4 transaction codes
| Code | Interpretation | Screen treatment |
|---|---|---|
| P | Open-market / private purchase | Buy evidence when the security is qualifying equity |
| S | Sale | Sell evidence when the security is qualifying equity |
| A | Grant / award | Context only |
| F | Tax-related withholding | Context only |
| M | Option exercise | Context only |
| G | Gift | Context only |
| J / L | Other / non-directional | Context only |
P/S rows for options, warrants, compensation units and debt remain visible for audit but are excluded from equity scores and quotes.